Evidence map›Paper›PMID 26330493›Full record

ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2016

Inhibitor of differentiation 1 transcription factor promotes metabolic reprogramming in hepatocellular carcinoma cells.

Bal Krishan Sharma, Ravindra Kolhe, Stephen M Black, Jonathan R Keller, Nahid F Mivechi, Ande Satyanarayana

Open access · greenAbstract read
In one paragraph

Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
1.3field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 45 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Inhibitor of Differentiation 1 (Id1) in Cancer and Cancer Therapy.International journal of medical sciences · 2020
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Bal Krishan Sharma*Department of Biochemistry and Molecular Biology, Molecular Oncology and Biomarkers Program, Georgia Regents University Cancer Center, Department of Pathology, and Program in Pulmonary Vascular Disease, Vascular Biology Center, Georgia Regents University, Augusta, Georgia, USA; and Basic Science Program, Leidos Biomedical Research, Incorporated, Mouse Cancer and Genetics Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
Ravindra Kolhe*Department of Biochemistry and Molecular Biology, Molecular Oncology and Biomarkers Program, Georgia Regents University Cancer Center, Department of Pathology, and Program in Pulmonary Vascular Disease, Vascular Biology Center, Georgia Regents University, Augusta, Georgia, USA; and Basic Science Program, Leidos Biomedical Research, Incorporated, Mouse Cancer and Genetics Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
Stephen M Black*Department of Biochemistry and Molecular Biology, Molecular Oncology and Biomarkers Program, Georgia Regents University Cancer Center, Department of Pathology, and Program in Pulmonary Vascular Disease, Vascular Biology Center, Georgia Regents University, Augusta, Georgia, USA; and Basic Science Program, Leidos Biomedical Research, Incorporated, Mouse Cancer and Genetics Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
Jonathan R Keller*Department of Biochemistry and Molecular Biology, Molecular Oncology and Biomarkers Program, Georgia Regents University Cancer Center, Department of Pathology, and Program in Pulmonary Vascular Disease, Vascular Biology Center, Georgia Regents University, Augusta, Georgia, USA; and Basic Science Program, Leidos Biomedical Research, Incorporated, Mouse Cancer and Genetics Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
Nahid F Mivechi*Department of Biochemistry and Molecular Biology, Molecular Oncology and Biomarkers Program, Georgia Regents University Cancer Center, Department of Pathology, and Program in Pulmonary Vascular Disease, Vascular Biology Center, Georgia Regents University, Augusta, Georgia, USA; and Basic Science Program, Leidos Biomedical Research, Incorporated, Mouse Cancer and Genetics Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
Ande Satyanarayana*Department of Biochemistry and Molecular Biology, Molecular Oncology and Biomarkers Program, Georgia Regents University Cancer Center, Department of Pathology, and Program in Pulmonary Vascular Disease, Vascular Biology Center, Georgia Regents University, Augusta, Georgia, USA; and Basic Science Program, Leidos Biomedical Research, Incorporated, Mouse Cancer and Genetics Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA sande@gru.edu.
Georgia Regents Medical Center · USMolecular Oncology (United States) · USAugusta University · USLeidos (United States) · US

Funding

Molecular-Cellular Regulation of Hematopoietic Stem CellsZIABC010001 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KELLER, JONATHAN R · 2009 to 2024
$16.8M
Role of heat shock transcription factor HSF1 in tumoroginesisR01CA062130 · NCI · MEDICAL COLLEGE OF GEORGIA (MCG) · PI MIVECHI, NAHID F, MOSKOFIDIS, DIMITRIOS · 1996 to 2025
$9.0M
PERINATAL REGULATION OF THE ENDOTHELIAL NOS GENER01HL060190 · NHLBI · UNIVERSITY OF MONTANA · PI Stephen M Black · 1998 to 2026
$7.1M
Role of heat shock factors (Hsfs) in tumorigenesisR01CA132640 · NCI · AUGUSTA UNIVERSITY · PI MIVECHI, NAHID F · 2008 to 2018
$2.7M
ROS in Pulmonary Hypertension: Role of ADMAR01HL067841 · NHLBI · UNIVERSITY OF MONTANA · PI BLACK, STEPHEN M · 2002 to 2011
$2.6M
A multifaceted approach to target obesityDP2DK105565 · NIDDK · AUGUSTA UNIVERSITY · PI ANDE, SATYANARAYANA · 2014 to 2014
$2.3M
Role of Id1 in adiposity, energy balance and obesity associated liver tumorigenesK22CA168828 · NCI · AUGUSTA UNIVERSITY · PI ANDE, SATYANARAYANA · 2013 to 2015
$382k
NCI NIH HHS K22 CA168828NCI NIH HHS K22CA168828NCI NIH HHS R01 CA062130NCI NIH HHS R01 CA132640NHLBI NIH HHS HL060190NHLBI NIH HHS R01 HL060190NHLBI NIH HHS R01 HL067841NIDDK NIH HHS DP2 DK105565
6 · The paper itself

Abstract

Reprograming of metabolism is one of the central hallmarks of cancer. The majority of cancer cells depend on high rates of glycolysis and glutaminolysis for their growth and survival. A number of oncogenes and tumor suppressors have been connected to the regulation of altered glucose and glutamine metabolism in cancer cells. For example, the oncogene c-Myc plays vital roles in cancer cell metabolic adaptation by directly regulating various genes that participate in aerobic glycolysis and glutaminolysis. Inhibitor of differentiation 1 (Id1) is a helix-loop-helix transcription factor that plays important roles in cell proliferation, differentiation, and cell fate determination. Overexpression of Id1 causes intestinal adenomas and thymic lymphomas in mice, suggesting that Id1 could function as an oncogene. Despite it being an oncogene, whether Id1 plays any prominent role in cancer cell metabolic reprograming is unknown. Here, we demonstrate that Id1 is strongly expressed in human and mouse liver tumors and in hepatocellular carcinoma (HCC) cell lines, whereas its expression is very low or undetectable in normal liver tissues. In HCC cells, Id1 expression is regulated by the MAPK/ERK pathway at the transcriptional level. Knockdown of Id1 suppressed aerobic glycolysis and glutaminolysis, suggesting that Id1 promotes a metabolic shift toward aerobic glycolysis. At the molecular level, Id1 mediates its metabolic effects by regulating the expression levels of c-Myc. Knockdown of Id1 resulted in down-regulation (∼75%) of c-Myc, whereas overexpression of Id1 strongly induced (3-fold) c-Myc levels. Interestingly, knockdown of c-Myc resulted in down-regulation (∼60%) of Id1, suggesting a positive feedback-loop regulatory mechanism between Id1 and c-Myc. Under anaerobic conditions, both Id1 and c-Myc are down-regulated (50-70%), and overexpression of oxygen-insensitive hypoxia-inducible factor 1α (Hif1α) or its downstream target Mxi1 resulted in a significant reduction of c-Myc and Id1 (∼70%), suggesting that Hif1α suppresses Id1 and c-Myc under anaerobic conditions via Mxi1. Together, our findings indicate a prominent novel role for Id1 in liver cancer cell metabolic adaptation.

Indexed as

AnimalsBasic Helix-Loop-Helix ProteinsCarcinoma, HepatocellularCell HypoxiaFeedback, PhysiologicalGlycolysisHep G2 CellsHumansHypoxia-Inducible Factor 1, alpha SubunitInhibitor of Differentiation Protein 1Liver NeoplasmsMaleMiceMice, Inbred C57BLOxygenProto-Oncogene Proteins c-mycBasic Helix-Loop-Helix ProteinsHypoxia-Inducible Factor 1, alpha SubunitInhibitor of Differentiation Protein 1Mxi1 protein, mouseOxygenProto-Oncogene Proteins c-mycTumor Suppressor Proteinsc-Mycglucose metabolismglutamine metabolismHif1αliver cancer

Identifiers

PMID26330493
PMCPMC4684534
OpenAlexW1253008772

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.